thyroid and semaglutide Compounded for Hypothyroid New Research Challenges Fears of

Gorriz, Maria Jose Soler, Secundino Cigarrn Guldris, Josep M

Mo1908: glucagon-like peptide-1 receptor agonist use in patients with perianal fistulizing Crohns disease is well tolerated and leads to weight loss and clinical improvement in fistula activity

Tapering the dose rather than stopping cold turkey may help mitigate the shock to the system, though evidence on this is still emerging

The trials arent head-to-head and long-term durability is still an open question, but a drug reaching surgical-range weight loss is genuinely new

Eli Lilly intends to submit regulatory applications for orforgliprons approval in weight management by the end of 2025, followed by an application for type 2 diabetes in 2026

Patients who wait until nausea subsidestypically after 48 weeks on a stable semaglutide dosegenerally tolerate alcohol better if they choose to drink